DDInter1729 DDInter1576
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Sulindac {u} (Compound) causes {v} (Side Effect) Protein urine present
Protein urine present {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Sulindac {u} (Compound) causes {v} (Side Effect) Protein urine present
Protein urine present {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Sulindac {u} (Compound) causes {v} (Side Effect) Gastroenteritis
Gastroenteritis {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Clomipramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Sulindac {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Dolutegravir
Dolutegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Regorafenib
Sulindac {u} (Compound) causes {v} (Side Effect) Hypertension
Hypertension {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Regorafenib
Sulindac {u} (Compound) causes {v} (Side Effect) Gastrointestinal perforation
Gastrointestinal perforation {u} (Side Effect) is caused by {v} (Compound) Ketorolac
Ketorolac {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Sulindac {u} (Compound) binds {v} (Gene) PTGDR2
PTGDR2 {u} (Gene) is bound by {v} (Compound) Indomethacin
Indomethacin {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Irinotecan
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Sulindac (Compound) causes Protein urine present (Side Effect) and Protein urine present (Side Effect) is caused by Regorafenib (Compound)
Sulindac (Compound) causes Protein urine present (Side Effect) and Protein urine present (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Regorafenib (Compound)
Sulindac (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Sulindac (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Dolutegravir (Compound) and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Regorafenib
Sulindac (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib
Sulindac (Compound) causes Gastrointestinal perforation (Side Effect) and Gastrointestinal perforation (Side Effect) is caused by Ketorolac (Compound) and Ketorolac may lead to a major life threatening interaction when taken with Regorafenib
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Regorafenib (Compound)
Sulindac (Compound) binds PTGDR2 (Gene) and PTGDR2 (Gene) is bound by Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Regorafenib
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Irinotecan (Compound) and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib